Health Check: Aussie biotechs are navigating a US regulatory minefield
Amplia raises $25 million, with another $2.5 million to go
A home-grown uni biotech innovation shines again
Telix Pharmaceuticals (ASX:TLX) shares this morning slumped up to 16% on news that the radiopharmacy play has attracted unwanted attention from the Securities and Exchange Commission (SEC).
But the company is no Robinson Crusoe, in that US regulatory and legal glitches pose a regular minefield for ASX biotechs doing business there.
The companies watchdog has subpoenaed 'various documents and information'. These mainly relate to the company's disclosures about its prostate cancer therapeutic program.
'The company is fully cooperating with the SEC and is in the process of responding to the information request,' Telix says.
'At this stage, this matter is a fact-finding request'.
Telix adds the SEC's entreaty does not mean that Telix has violated US security laws 'or that the SEC has a negative opinion of any person, entity or security'.
Barring more detail, the episode sounds like a case of 'probably nothing or very much something'.
Overnight, Nasdaq investors were more chill about the affair, marking Telix shares only marginally lower.
At the very least, the SEC's nosing around is likely to distract management from the company's busy agenda.
'In our experience of similar matters, these investigations tend to drag on for years without resolution,' broker Jefferies says.
Trouble and strife
Other ASX biotechs in the US have run into the odd bit of strife over patent disputes and regulatory interventions.
ResMed (ASX:RMD) regularly parries with rivals Fisher & Paykel Healthcare (ASX:FPH) and Philips Respironics over sleep apnoea patents.
In 2018 a jury ordered Cochlear (ASX:COH) to pay US$268 million in damages for a patent infringement. The charitable Alfred E. Mann Foundation lodged the action.
In 2020 Cochlear lost an appeal.
In 2013 CSL (ASX:CSL) paid US$64 million to settle an antitrust class action lodged by hospital groups.
'Business as usual'
Telix says it will continue with the prostate cancer program. The SEC action also will not affect its nearer-stage imaging programs for kidney and brain cancers.
Telix also reported June quarter revenue of US$204 million, 63% higher year on year, whilst maintaining calendar 2025 revenue guidance of US$770-800 million.
This revenue derived mainly from Telix's prostate cancer imaging agent, Illucix.
'Dose volumes for Illuccix rose 7% quarter-on-quarter in the US, reinforcing the strength of our market position and continued customer demand,' Telix co-founder and CEO Dr Chris Behrenbruch says.
He adds that 'despite emerging competitive pricing pressure', Telix has 'effective strategies' to maintain average selling prices.
Next month, Telix lifts the kimono on June (first) half earnings.
Jefferies expects a $50.6 million net profit, with a calendar 2025 tally of $88.3 million.
Interestingly, this is a decline on the previous year's US$105.4 million, but the firm plugs in US$183 million for calendar 2026.
Perhaps they lost our phone number?
Speaking of US regulatory glitches, stroke drug developer Argenica Therapeutics (ASX:AGN) is yet to hear back from the US Food and Drug Administration (FDA) as to why the agency plonked a 'clinical hold' on its US trial plans.
On June 10 Argenica said the FDA had deemed the company's supportive material as not being adequate to support its Investigational New Drug application.
The trial was aimed at approval under the FDA's fast-track route.
Argenica expected to hear back from the FDA within 30 days, but the agency's 'resourcing challenges' have blown out this timeline.
In the meantime, Argenica is on track to report topline results from its local, proof-of-concept trial in the current quarter.
The 92-patient phase II study tests Argenica's candidate ARG-007, in view of safety and preliminary efficacy in ischaemic (blockage) stroke patients.
Courtesy of $4 million of government and private grants, Argenica is also investigating the 'potential utility' of ARG-0007 for other neurological conditions, including traumatic brain injury.
Argenica disclosed June quarter cash burn of $2.36 million and a closing cash balance of $10.5 million.
Nyrada advances heart protection trial
In other trial news, Nyrada (ASX:NYR) is advancing its locally developed drug Xolatryp into phase IIa stage.
Xolatryp targets the unmet need of protecting the heart following cardiac injury where patients are at high risk of tissue damage.
Nyrada notes there's been no significant new cardiac drug developed for more than two decades.
Xolatryp could become the first drug of its kind to protect the heart actively from ischemia-reperfusion injury.
Nyrada anticipates a randomised, double-blind, placebo-controlled study, enrolling 150 subjects.
These patients have acute myocardial infarction undergoing percutaneous coronary intervention (stenting).
The company hopes to kick off the study in the March quarter of 2026.
We now have Ample-ia funds, says cancer drug developer
Prostate cancer drug hopeful Amplia (ASX:ATX) has raised $25 million in an institutional placement and is eyeing a further $2.5 million in a share purchase plan.
The deed was done at 23 cents, a 19% discount to last Friday's 'frozen' price ahead of a trading halt.
Amplia shares have been on a tear on the back of remarkable phase II results, covering patients with advanced metastatic forms of the deadly disease.
Last month Amplia reported 17 partial responses, which meant the tumour size shrunk by at least 30%.
Two of the 55 patients reported a complete response, which pretty much means a – can we say it? – cure.
Amplia now plans a US trial combining Amplia's candidate AMP-945 with a different chemotherapy.
The raising takes Amplia's cash to $42.7 million, including $8.2 million of expected R&D tax refunds.
Don't forget who invented it
Sanofi's $2.5 billion purchase of vaccine tech outfit Vicebio again highlights the role of Australian universities as a springboard for money-making life sciences ideas.
The Paris-based Big Pharma is paying up to US$1.6 billion for the UK-based Vicebio and its so-called molecular clamp technology.
The deal involves an upfront payment of US$1.15 billion, with regulatory milestones of US$450 million.
Discovered at the University of Queensland (UQ), the clamp stabilises viral proteins enabling the immune system to respond to them more effectively.
The upshot is the quicker development of fully liquid combination vaccines that can be stored at fridge temperatures.
Vicebio was formed in 2018 to develop the clamp to make vaccines against life-threatening respiratory viral infections.
During the pandemic, Vicebio had a stab at a Covid-19 vaccine.
Courtesy of a US$100 million Series B financing last year, Vicebio's investors include Goldman Sachs Alternatives, Avoro Ventures and Venbio Partners.
Uniquest, UQ's commercialisation arm has an unquantified direct investment and benefits from a licensing arrangement.
Uniquest formed more than 130 start-ups, which went on to raise more than $1 billion and glean $86 million in product sales.
This included licensing the UQ-invented cervical cancer vaccine Gardasil.
The UQ bright sparks responsible for the molecular clamp are professors Paul Young, Daniel Watterson and Keith Chappell.
UQ describes the deal as 'the largest involving a company that is commercialising intellectual property from an Australian university.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
Why does everyone get sick so often in winter?
Welcome to Ask Doctor Zac, a weekly column from This week, Dr Zac Turner explores why so many people get sick in the winter. QUESTION: Hi Dr Zac, Every winter like clockwork, my sharehouse becomes a snotty, coughing mess. I always assumed it was just because me and my flatties are inside more, but I read something about viruses surviving longer in colder temperatures. Is that true? And does the lack of sun during winter actually mess with our immune systems? – Matt, 29, Ballarat VIC ANSWER: Thanks for the question, Matt – and condolences to your household's sinuses. Winter really does bring with it a revolving door of colds, flus and respiratory infections. It's not your imagination. And while yes, spending more time indoors definitely helps viruses spread, the science of why we get sicker in winter runs a bit deeper – and chillier – than that. Let's start with the temperature. Many common viruses, including rhinoviruses (the ones behind most colds) and influenza, actually survive longer and replicate more effectively in colder, drier conditions. One study from the Journal of Virology found that some viruses become more stable and infectious in lower temperatures because the cold preserves the viral envelope – essentially giving them a longer shelf life while they search for their next victim (you). Add in the fact that we're all breathing the same stale air indoors, and it's a perfect storm: less ventilation, more close contact, and viruses that are thriving in the cold. Now, let's talk about vitamin D. This isn't some wellness influencer's pet obsession – it's genuinely important for your immune function. Vitamin D helps regulate immune responses, and deficiency has been linked to increased susceptibility to infections, particularly respiratory ones. In winter, shorter daylight hours and less skin exposure to UVB rays means your body produces less vitamin D naturally. In fact, data from the Australian Bureau of Statistics shows nearly one in four Aussies have insufficient vitamin D during the colder months – especially in southern regions like Victoria and Tasmania. So yes, Matt: cold temperatures, indoor living, and low vitamin D levels all team up to make winter a bit of a microbial minefield. What can you do about it? • Maximise ventilation: Even cracking a window makes a difference. Let your house breathe. Get outside during daylight hours: A lunchtime walk could help top up your vitamin D – just 10–15 minutes of sun exposure to arms and face can help. • Eat immune-supporting foods: Fatty fish, eggs, mushrooms and fortified milks are great sources of vitamin D. And yes, supplements are helpful if you're deficient – but check with your GP before starting. • Practice good hygiene: Wash hands, cover coughs, and maybe don't share that water bottle with your sniffling housemate. A few smart habits can help make your winter less snotty – and keep your immune system in fighting form until the sun comes back. Stay warm, Dr Zac Dr Zac Turner is a medical practitioner specialising in preventative health and wellness. He has four health/medical degrees – Bachelor of Medicine/Bachelor of Surgery at the University of Sydney, Bachelor of Nursing at Central Queensland University, and Bachelor of Biomedical Science at the University of the Sunshine Coast. He is a registrar for the Australian College of Rural and Remote Medicine, and is completing a PhD in Biomedical Engineering (UNSW). Dr Zac is the medical director for his own holistic wellness medical clinics throughout Australia, Concierge Doctors.
News.com.au
3 hours ago
- News.com.au
Labor to introduce Bill to cap PBS-listed scripts at $25, PM dodges questions on super tax
Labor will begin its first steps to legislate its election promise to cap the cost of scripts listed on the Pharmaceutical Benefits Scheme to $25 from January 1 of next year. Once passed, eligible medicines will be lowered from $31.60 to $25. The government estimates the change will save Australians $200m a year, while costing the budget $690m over four years. This is in addition to previous reforms which allowed patients to acquire 60-day prescriptions, and freezing the cost of medicine for pension and concession card holders at $7.70 until the end of 2029. The election pledge was also matched by the Coalition, suggesting the Bill will likely have a swift passage through parliament. Anthony Albanese said it was a promise delivered. 'This is another example of cost of living relief that helps every Australian,' Mr Albanese said. 'The size of your bank balance shouldn't determine the quality of your healthcare. My government will continue to deliver cost of living relief for all Australians.' Health Minister Mark Bulter also welcomed the incoming Bill. 'Cheaper medicines are good for the hip pocket and good for your health,' Mr Butler said. 'For general patients medicines haven't been this cheap since 2004. 'For pension and concession card holders we've frozen your medicine prices at a maximum price of $7.70 until the end of the decade.' The Bill comes as the United States lashed Australia's PBS as 'discriminatory' amid tariff negotiations to remove the general 10 per cent levy, as well as fees on Australian steel and aluminium US imports. Concerningly, US President Donald Trump has also flagged a 200 per cent tariff on pharmaceutical imports, which could have a major impact on $2bn of Australian exports. However the Albanese government said it is unwilling to use the PBS as a bargaining chip. On Sunday, Mr Albanese also faced a grilling over when Labor would introduce its proposed plan to double the tax on superannuation accounts over $3m up to 30 per cent. He said the Bill 'will come in time' and that the priority in the first fortnight was policies 'that make a difference to people's money in their pocket'. Perth MP and assistant minister to the Prime Minister Patrick Gorman said the government had been 'clear about our priorities' for the Bill and said he was 'confident it will pass'. 'I think we have seen in this building, time and time again, that when it comes to getting things through parliament, you have got to also let the parliamentary processes do their piece,' he said.
AU Financial Review
6 hours ago
- AU Financial Review
ASX seeks to calm investor anger with changes to listing rule waivers
The ASX is taking an initial, but important, step to calm investor anger over the hot-button issue of the bourse's granting of waivers to the listing rules. In April, the embattled ASX began conducting a wholesale review of the nation's listing rules, following a fierce backlash over James Hardie's $13 billion purchase of American company Azek. In that instance, a waiver was granted that allowed James Hardie to bypass a shareholder vote, issue new shares and make a wildly unpopular acquisition.
